<?xml version='1.0' encoding='utf-8'?>
<document id="30605231"><sentence text="The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer."><entity charOffset="23-31" id="DDI-PubMed.30605231.s1.e0" text="tyrosine" /></sentence><sentence text="The concomitant use of tyrosine kinase inhibitors (TKIs) and proton pump inhibitors (PPIs) is a significant concern because of potential drug-drug interaction that reduces TKI absorption, thus potentially reducing the effectiveness of TKIs"><entity charOffset="23-31" id="DDI-PubMed.30605231.s2.e0" text="tyrosine" /></sentence><sentence text=" The objective of this study was to evaluate the prevalence and predictors of concomitant TKI-PPI receipt and its impact on survival and therapy discontinuation in older adults with cancer" /><sentence text="" /><sentence text="This retrospective study used linked Surveillance, Epidemiology, and End Results-Medicare data for the years 2007 through 2012" /><sentence text=" In total, 12,538 patients with lung cancer, renal cell cancer, chronic myelogenous leukemia, liver cancer, or pancreatic cancer were included" /><sentence text=" The primary exposure variable was concomitant receipt of TKI-PPI, defined as at least 30 days of PPI use in the first 90 days from the start of the TKI (exposure period)" /><sentence text=" The outcomes measured were overall survival and discontinuation of therapy in 90 days and 1 year after the end of the exposure period" /><sentence text=" Cox proportional-hazards regression with inverse probability of treatment weighting was used to evaluate the association between exposure and outcome" /><sentence text="" /><sentence text="The overall prevalence of TKI-PPI receipt was 22" /><sentence text="7%" /><sentence text=" Predictors that were associated with increased use included polypharmacy and prior PPI receipt" /><sentence text=" TKI-PPI use decreased survival in 90 days (hazard ratio, 1" /><sentence text="16; 95% confidence interval, 1" /><sentence text="05-1" /><sentence text="28) and in 1 year (hazard ratio, 1" /><sentence text="10; 95% confidence interval, 1" /><sentence text="04-1" /><sentence text="18) but was not associated with discontinuation" /><sentence text="" /><sentence text="Nearly 1 in 4 older adults with cancer who receive TKIs also receive PPIs concomitantly, and concomitant use is associated with an increased risk of death" /><sentence text=" Concerted efforts to manage medications are needed to identify and reduce the receipt of PPIs when TKIs are initiated" /><sentence text="" /></document>